浙江医药
(600216)
| 流通市值：129.05亿 | | | 总市值：129.05亿 |
| 流通股本：9.62亿 | | | 总股本：9.62亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 7,112,804,346.3 | 4,405,467,286.37 | 2,249,164,467.2 | 7,794,145,971.37 |
| 营业收入 | 7,112,804,346.3 | 4,405,467,286.37 | 2,249,164,467.2 | 7,794,145,971.37 |
| 二、营业总成本 | 6,103,341,032.99 | 4,013,409,994.55 | 2,131,384,649.46 | 7,681,665,559.36 |
| 营业成本 | 4,263,783,893.03 | 2,846,185,174.17 | 1,508,814,448.88 | 5,269,878,689.98 |
| 税金及附加 | 67,949,429 | 39,153,409.49 | 20,531,870.82 | 78,428,557.7 |
| 销售费用 | 849,542,121.05 | 537,172,530.81 | 288,699,872.16 | 1,045,588,220.72 |
| 管理费用 | 378,004,987.39 | 221,357,666.04 | 115,116,312.58 | 445,186,095.66 |
| 研发费用 | 546,930,073.32 | 377,483,069.83 | 196,215,236.98 | 860,072,434.06 |
| 财务费用 | -2,869,470.8 | -7,941,855.79 | 2,006,908.04 | -17,488,438.76 |
| 其中:利息费用 | 21,452,543.87 | 14,987,999.93 | 6,800,707.12 | 28,384,141.56 |
| 其中:利息收入 | 15,437,521.94 | 9,470,893.59 | 4,788,911.88 | 16,512,032.57 |
| 加:公允价值变动收益 | -3,578,166.01 | -11,590,057.79 | -6,963,214.95 | -10,099,353.1 |
| 加:投资收益 | -16,218,180.83 | -11,609,733.51 | -1,500,647.53 | -3,504,843.76 |
| 资产处置收益 | -818,044.51 | -958,361.51 | -849,636.57 | 330,155,867.41 |
| 资产减值损失(新) | -101,489,942.48 | -67,109,016.06 | -26,259,889.15 | -137,208,398.87 |
| 信用减值损失(新) | 191,890.43 | 275,244.2 | -1,887,221.37 | 28,214,492.4 |
| 其他收益 | 49,525,376.3 | 40,367,983.26 | 21,478,602.1 | 60,120,089.01 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 937,076,246.21 | 341,433,350.41 | 101,797,810.27 | 380,158,265.1 |
| 加:营业外收入 | 2,838,193.62 | 492,760.28 | 282,569.5 | 1,795,020.58 |
| 减:营业外支出 | 9,109,174.45 | 7,336,808.26 | 1,035,915.32 | 18,674,578.73 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 930,805,265.38 | 334,589,302.43 | 101,044,464.45 | 363,278,706.95 |
| 减:所得税费用 | 172,247,182.7 | 79,223,834.42 | 21,681,136.59 | 86,484,579.11 |
| 六、净利润 | 758,558,082.68 | 255,365,468.01 | 79,363,327.86 | 276,794,127.84 |
| 持续经营净利润 | 758,558,082.68 | 255,365,468.01 | 79,363,327.86 | 276,794,127.84 |
| 归属于母公司股东的净利润 | 849,651,818.01 | 315,332,017.87 | 109,649,638.31 | 429,639,626.26 |
| 少数股东损益 | -91,093,735.33 | -59,966,549.86 | -30,286,310.45 | -152,845,498.42 |
| (一)基本每股收益 | 0.88 | 0.33 | 0.11 | 0.45 |
| (二)稀释每股收益 | 0.88 | 0.33 | 0.11 | 0.45 |
| 八、其他综合收益 | -1,441,540.27 | -4,263,504.68 | -3,950,569.56 | 11,713,075.31 |
| 归属于母公司股东的其他综合收益 | -1,385,792.03 | -3,988,084.3 | -3,706,960.26 | 11,043,585.59 |
| 九、综合收益总额 | 757,116,542.41 | 251,101,963.33 | 75,412,758.3 | 288,507,203.15 |
| 归属于母公司股东的综合收益总额 | 848,266,025.98 | 311,343,933.57 | 105,942,678.05 | 440,683,211.85 |
| 归属于少数股东的综合收益总额 | -91,149,483.57 | -60,241,970.24 | -30,529,919.75 | -152,176,008.7 |
| 公告日期 | 2024-10-25 | 2024-08-23 | 2024-04-26 | 2024-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |